NewAmsterdam Pharma Company N.V. (id:6662 NAMS)
20.12 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/22/2024 2:12:21 AM)
Exchange closed, opens in 7 hours 17 minutes
About NewAmsterdam Pharma Company N.V.
Market Capitalization 2.31B
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
| Headquarters (address) |
Gooimeer 2-35 Naarden 1411 DC Netherlands |
| Phone | 31 35 206 2971 |
| Website | https://www.newamsterdampharma.com |
| Employees | 29 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | NAMS |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 8.90 - 26.35 |
| Market Capitalization | 2.31B |
| Dividend yield forward | 6.59 % |
| Dividend yield forward Netherlands (ID:23, base:66) | 12.48 % |
| P/E trailing | -9.31 |
| P/E forward | -13.21 |
| Price/Sale | 68.67 |
| Price/Book | 6.07 |
| Beta | -0.001 |
| EPS | -2.24 |
| EPS Netherlands (ID:23, base:87) | 1.63 |
Forward Annual Dividend Yield
Forward Annual Dividend Yield: NewAmsterdam Pharma Company N.V. has raised their dividend 6.59 years in a row. This is below the 41133.782300 year average in the 'Biotechnology' industry
Forward Annual Dividend Yield
Forward Annual Dividend Yield: NewAmsterdam Pharma Company N.V. has raised their dividend 6.59 years in a row. This is below the 41133.782300 year average in the 'Biotechnology' industry